TransThera Sciences (Nanjing), Inc. (HKG:2617)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
192.00
-2.20 (-1.13%)
At close: Dec 5, 2025
Market Cap 76.20B
Revenue (ttm) n/a
Net Income (ttm) -259.80M
Shares Out 396.90M
EPS (ttm) -0.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 169,660
Average Volume 824,662
Open 197.00
Previous Close 194.20
Day's Range 191.20 - 197.00
52-Week Range 20.20 - 679.50
Beta n/a
RSI 48.53
Earnings Date Nov 25, 2025

About HKG:2617

TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 121
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2617
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.